Pharmacological doses of gamma-hydroxybutyrate (GHB) potentiate histone acetylation in the rat brain by histone deacetylase inhibition

Neuropharmacology

Volumn 57, Issue 2, 2009, Pages 137-147

  Klein, Christian ^a   Kemmel, Véronique ^a   Taleb, Omar ^a   Aunis, Dominique ^a   Maitre, Michel ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Brain stem; Cerebellum; Gamma hydroxybutyrate; GHB; HDAC inhibition; Hippocampus; Histone acetylation

Indexed keywords

4 HYDROXYBUTYRIC ACID; HISTONE DEACETYLASE; HISTONE H3;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT;

ACETYLATION; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; BRAIN; BRAIN STEM; CENTRAL NERVOUS SYSTEM AGENTS; CEREBELLUM; CEREBRAL CORTEX; CHROMATOGRAPHY; HIPPOCAMPUS; HISTONE DEACETYLASES; HISTONES; IMMUNOHISTOCHEMISTRY; MALE; NEURONS; RATS; RATS, WISTAR; SODIUM OXYBATE; TIME FACTORS;

EID: 67650421510     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.04.013     Document Type: Article

References (51)

1. Abanades S., Farre M., Segura M., Pichini S., Barral D., Pacifici R., Pellegrini M., Fonseca F., Langohr K., and De La Torre R. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann. N. Y. Acad. Sci. 1074 (2006) 559-576
2. Addolorato G., Castelli E., Stefanini G.F., Casella G., Caputo F., Marsigli L., Bernardi M., and Gasbarrini G. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. Alcohol Alcohol. 31 (1996) 341-345 GHB Study Group
3. Anderson I.B., Kim S.Y., Dyer J.E., Burkhardt C.B., Iknoian J.C., Walsh M.J., and Blanc P.D. Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003. Ann. Emerg. Med. 47 (2006) 177-183
4. Andriamampandry C., Taleb O., Viry S., Muller C., Humbert J.P., Gobaille S., Aunis D., and Maitre M. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). FASEB J. 17 (2003) 1691-1693
5. Andriamampandry C., Taleb O., Kemmel V., Humbert J.P., Aunis D., and Maitre M. Cloning and functional characterization of a gamma-hydroxybutyrate receptor identified in the human brain. FASEB J. 21 (2007) 885-895
6. Arts J., Angibaud P., Marien A., Floren W., Janssens B., King P., van Dun J., Janssen L., Geerts T., Tuman R.W., Johnson D.L., Andries L., Jung M., Janicot M., and van Emelen K. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br. J. Cancer. 97 (2007) 1344-1353
7. Balasubramaniyan V., Boddeke E., Bakels R., Kust B., Kooistra S., Veneman A., and Copray S. Effects of histone deacetylation inhibition on neuronal differentiation of embryonic mouse neural stem cells. Neuroscience 143 (2006) 939-951
8. Basaki Y., Chikahisa L., Aoyagi K., Miyadera K., Yonekura K., Hashimoto A., Okabe S., Wierzba K., and Yamada Y. gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis 4 (2001) 163-173
9. Borgen L.A., Okerholm R.A., Lai A., and Scharf M.B. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. J. Clin. Pharmacol. 44 (2004) 253-257
10. Brenneisen R., Elsohly M.A., Murphy T.P., Passarelli J., Russmann S., Salamone S.J., and Watson D.E. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J. Anal. Toxicol. 28 (2004) 625-630
11. Broide R.S., Redwine J.M., Aftahi N., Young W., Bloom F.E., and Winrow C.J. Distribution of histone deacetylases 1-11 in the rat brain. J. Mol. Neurosci. 31 (2007) 47-58
12. Cash C.D., Gobaille S., Kemmel V., Andriamampandry C., and Maitre M. Gamma-hydroxybutyrate receptor function studied by the modulation of nitric oxide synthase activity in rat frontal cortex punches. Biochem. Pharmacol. 58 (1999) 1815-1819
13. Dokmanovic M., and Marks P.A. Prospects: histone deacetylase inhibitors. J. Cell. Biochem. 96 (2005) 293-304
14. Drasbek K.R., Christensen J., and Jensen K. Gamma-hydroxybutyrate-a drug of abuse. Acta Neurol. Scand. 114 (2006) 145-156
15. Eyal S., Yagen B., Sobol E., Altschuler Y., Shmuel M., and Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45 (2004) 737-744
16. Facchetti F., Previdi S., Ballarini M., Minucci S., Perego P., and La Porta C.A. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 9 (2004) 573-582
17. Fung H.L., Haas E., Raybon J., Xu J., and Fung S.M. Liquid chromatographic-mass spectrometric determination of endogenous gamma-hydroxybutyrate concentrations in rat brain regions and plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci. 807 (2004) 287-291
18. Gaiddon C., Larmet Y., Trinh E., Boutillier A.L., Sommer B., and Loeffler J.P. Brain-derived neurotrophic factor exerts opposing effects on beta2-adrenergic receptor according to depolarization status of cerebellar neurons. J. Neurochem. 73 (1999) 1467-1476
19. Gallimberti L., Canton G., Gentile N., Ferri M., Cibin M., Ferrara S.D., Fadda F., and Gessa G.L. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet 2 (1989) 787-789
20. Gibson K.M., Gupta M., Pearl P.L., Tuchman M., Vezina L.G., Snead III O.C., Smit L.M., and Jakobs C. Significant behavioral disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria). Biol. Psychiatry. 54 (2003) 763-768
21. Hrzenjak A., Moinfar F., Kremser M.L., Strohmeier B., Staber P.B., Zatloukal K., and Denk H. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Ther. 5 (2006) 2203-2210
22. Huang L. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J. Cell. Physiol. 209 (2006) 611-616
23. Kemmel V., Taleb O., Andriamampandry C., Aunis D., and Maitre M. Gamma-hydroxybutyrate receptor function determined by stimulation of rubidium and calcium movements from NCB-20 neurons. Neuroscience 116 (2003) 1021-1031
24. Kim H.J., Rowe M., Ren M., Hong J.S., Chen P.S., and Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321 (2007) 892-901
25. Kleinschmidt S., Grundmann U., Janneck U., Kreienmeyer J., Kulosa R., and Larsen R. Total intravenous anaesthesia using propofol, gamma-hydroxybutyrate or midazolam in combination with sufentanil for patients undergoing coronary artery bypass surgery. Eur. J. Anaesthesiol. 14 (1997) 590-599
26. Lettieri J.T., and Fung H.L. Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. J. Pharmacol. Exp. Ther. 208 (1979) 7-11
27. Levy M.I., Davis B.M., Mohs R.C., Trigos G.C., Mathe A.A., and Davis K.L. Gamma-hydroxybutyrate in the treatment of schizophrenia. Psychiatry Res. 9 (1983) 1-8
28. Lingenhoehl K., Brom R., Heid J., Beck P., Froestl W., Kaupmann K., Bettler B., and Mosbacher J. Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors. Neuropharmacology 38 (1999) 1667-1673
29. Lobina C., Colombo G., Brunetti G., Diaz G., Melis S., Pani M., Serra S., Vacca G., Gessa G.L., and Carai M.A. Procedure of bidirectional selective outbreeding for production of two rat lines differing in sensitivity to the sedative/hypnotic effect of gamma-hydroxybutyric acid. Brain Res. Protoc. 8 (2001) 74-81
30. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16 (2002) 669-694
31. 2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J. Med. Chem. 47 (2004) 467-474
32. Mamelak M., Scharf M.B., and Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 9 (1986) 285-289
33. Muller C., Viry S., Miehe M., Andriamampandry C., Aunis D., and Maitre M. Evidence for a gamma-hydroxybutyrate (GHB) uptake by rat brain synaptic vesicles. J. Neurochem. 80 (2002) 899-904
34. Nelson T., Kaufman E., Kline J., and Sokoloff L. The extraneural distribution of gamma-hydroxybutyrate. J. Neurochem. 37 (1981) 1345-1348
35. Ottani A., Saltini S., Bartiromo M., Zaffe D., Renzo Botticelli A., Ferrari A., Bertolini A., and Genedani S. Effect of gamma-hydroxybutyrate in two rat models of focal cerebral damage. Brain Res. 986 (2003) 181-190
36. Palkovits M., and Brownstein M.J. Maps and Guide to Microdissection of the Rat Brain (1988), Elsevier, New York-Amsterdam-London
37. Pandey S.C., Ugale R., Zhang H., Tang L., and Prakash A. Brain chromatin remodeling: a novel mechanism of alcoholism. J. Neurosci. 28 (2008) 3729-3737
38. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. second edition (1986), Academic Press, New York
39. Raybon J.J., and Boje K.M. Pharmacokinetics and pharmacodynamics of gamma-hydroxybutyric acid during tolerance in rats: effects on extracellular dopamine. J. Pharmacol. Exp. Ther. 320 (2007) 1252-1260
40. Robinson D.M., and Keating G.M. Sodium oxybate: a review of its use in the management of narcolepsy. CNS Drugs 21 (2007) 337-354
41. Sadasivan S., Maher T.J., and Quang L.S. Gamma-hydroxybutyrate (GHB), gamma-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) reduce the volume of cerebral infarction in rodent transient middle cerebral artery occlusion. Ann. N. Y. Acad. Sci. 1074 (2006) 537-544
42. Saha R.N., and Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ. 13 (2006) 539-550
43. Schulz S.C., van Kammen D.P., Buchsbaum M.S., Roth R.H., Alexander P., and Bunney Jr. W.E. Gamma-hydroxybutyrate treatment of schizophrenia: a pilot study. Pharmacopsychiatria 14 (1981) 129-134
44. Shumate J.S., and Snead III O.C. Plasma and central nervous system kinetics of gamma-hydroxybutyrate. Res. Commun. Chem. Pathol. Pharmacol. 25 (1979) 241-256
45. Simonini M.V., Camargo L.M., Dong E., Maloku E., Veldic M., Costa E., and Guidotti A. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1587-1592
46. Smirnova I.V., Bittel D.C., Ravindra R., Jiang H., and Andrews G.K. Zinc and cadmium can promote rapid nuclear translocation of metal response element-binding transcription factor-1. J. Biol. Chem. 275 (2000) 9377-9384
47. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., and Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150 (1985) 76-85
48. Vayer P., Mandel P., and Maitre M. Conversion of gamma-hydroxybutyrate to gamma-aminobutyrate in vitro. J. Neurochem. 45 (1985) 810-814
49. Vayer P., Ehrhardt J.D., Gobaille S., Mandel P., and Maitre M. Gamma-hydroxy-butyrate distribution and turnover rates in discrete brain regions of the rat. Neurochem. Int. 12 (1988) 53-59
50. Wong C.G., Gibson K.M., and Snead III O.C. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol. Sci. 25 (2004) 29-34
51. Zhu W.G., Lakshmanan R.R., Beal M.D., and Otterson G.A. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 61 (2001) 1327-1333